| Literature DB >> 33369454 |
Weerin Sawangkajohn1, Vor Luvria1, Natwutpong Leeratanakachorn2, Theerawee Tipwaratorn1, Suapa Theerakul1, Apiwat Jarearnrat1, Attapol Titapun1, Tharatip Srisuk1, Ake Pugkhem1, Narong Khuntikeo1, Vajarabhongsa Bhudhisawasdi1, Supot Kamsa-Ard3.
Abstract
OBJECTIVE: All types of cholangiocarcinoma (CCA) require a major hepatectomy, which has many post-operative complications. All complications usually present with persistent hyperbilirubinemia; however, studies on the prediction of post-operative hyperbilirubinemia after hepatectomy for patients with CCA are lacking. We evaluated the causes and patterns of persistent hyperbilirubinemia among the patients who underwent hepatectomy for CCA.Entities:
Keywords: Bilirubin; Liver failure; cholangiocarcinoma; hepatectomy; survival
Year: 2020 PMID: 33369454 PMCID: PMC8046309 DOI: 10.31557/APJCP.2020.21.12.3573
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1Patterns of Persistent Hyperbilirubinemia. a) increasing b) decreasing c) ‘peak’ pattern d) ‘V’ pattern e) persistent
Figure 2Proportion of Persistent Hyperbilirubinemia and Its Causes
Association between Patterns of Bilirubin Level and Causes of Hyperbilirubinemia
| Cause | Pattern | ||||
|---|---|---|---|---|---|
| Increasing | Decreasing | Peak | V-shape | Persist | |
| Liver Failure | 4 (57.1%) | 2 (22.2%) | 2 (66.7%) | 6 (85.7%) | 0 (0%) |
| Bile leakage | 1 (14.3%) | 1 (11.1%) | 1 (33.3%) | 1 (14.3%) | 0 (0%) |
| Stricture/ cholangitis | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) |
| Unspecified | 2 (28.6%) | 6 (66.7%) | 0 (0%) | 0 (0%) | 1 (50%) |
Figure3Kaplan-Meier Survival Curve of Cholangiocarcinoma Patients Treated by Hepatic Resection Stratified by the Pattern of Persistent Hyperbilirubinemia
Clinical and Operative Data
| Variables | Normal | Liver failure | Bile leakage | Stricture/ Cholangitis | Unspecified |
|---|---|---|---|---|---|
| Age (mean. SD) | 62.8 (8.4) | 58.4 (6.1) | 65.0 (5.7) | 68 (-) | 58.4 (9.6) |
| Gender (male)(%) | 50 (56.8) | 10 (71.4) | 4 (100) | 1 (100) | 7(77.8) |
| Location (%) | |||||
| Intrahepatic | 51 (57.9) | 0 (0) | 1 (25) | 0 (0) | 0(0) |
| Perihilar | 37 (42.0) | 14 (100) | 3 (75) | 1 (100) | 9(100) |
| Type of CCA (%) | |||||
| MF | 12 (13.6) | 0 (0) | 0 (0) | 0 (0) | 0(0) |
| PI/ FN | 18 (20.5) | 9 (64.3) | 1 (25) | 0 (0) | 5(55.6) |
| IG/ PP | 58 (65.9) | 5 (35.7) | 3 (75) | 1 (100.0) | 4(44.4) |
| Procedure (%) | |||||
| Right hepatectomy | 38 (43.2) | 4 (28.6) | 2 (50.0) | 1 (100.0) | 2(22.2) |
| Extended Right hepatectomy | 9 (10.2) | 5 (35.7) | 1 (25.0) | 0 (0.0) | 3(33.3) |
| Right trisectionectomy | 5 (5.7) | 4 (28.6) | 1 (25.0) | 0 (0.0) | 2(22.2) |
| Left hepatectomy | 28 (31.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1(11.1) |
| Extended Left hepatectomy | 2 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1(11.1) |
| Left trisectionectomy | 1 (1.1) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0(0.0) |
| Other | 5 (5.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0(0.0) |
| Vascular resection (%) | 3 (3.4) | 3 (21.4) | 0 (0.0) | 0 (0.0) | 2(22.2) |
| Vascular inflow occlusion (%) | 35 (39.8) | 4 (28.6) | 3 (75) | 1 (100) | 3(33.3) |
| IVC Clampimg (%) | 20 (22.7) | 3 (21.4) | 1 (25.0) | 0 (0.0) | 2(22.2) |
| EBL (ml)(SD) | 524.2 (351.6) | 880.0 (775.2) | 675.0 (562.0) | 1300.0 (-) | 1088.9 (506.1) |
| LOS(days)(SD) | 11.2 (5.1) | 21.2 (9.8) | 18.0 (9.0) | 45 (-) | 13.0 (5.0) |
| Preoperative laboratory investigation (median: min-max) | |||||
| Total biliarubin (mg/dl) | 0.7 (0.2-3.5) | 4.1 (1.2- 8.3) | 1.65 (0.5-3.8) | 19.3 (19.3 -19.3) | 4.9 (1.8 -8.6) |
| AST (u/L) | 196 (23 -1290) | 469 (177-1283) | 623 (139-2552) | 1289 (1289-1289) | 493 (114-738) |
| ALT (u/L) | 125 (35-1190) | 275.5 (92-633) | 359 (62-1568) | 746 (746-746) | 302 (72-632) |
| ALP (u/L) | 94.5 (39- 511) | 146.5 (61-350) | 132.5 ( 87-225) | 110 (110- 110) | 174 (109-605) |
| Albumin (g/dl) | 2.8 (1.7- 4.3) | 2.6(1.9-3.3) | 2.9 (2.4- 4.4) | 2 (2-2) | 2.4 (2.2- 3.5) |
| Cholesterol (mg/dl) | 135.5 (60-275) | 119 (89-205) | 136.5 (98-175) | 90 (90-90) | 113 (60-156) |
| Postoperative Total bilirubin | |||||
| Postoperative day 1 | 1.4 (0.3-5.1) | 5.75 (2-16) | 3.2 (1-6.6) | 27.7 (27.7-27.7) | 6.6 (3.1-12.9) |
| Postoperative day 3 | 1 (0.3-4.4) | 6.45 (1.3-10.1) | 3.45 (0.9-6.7) | 24.8 (24.8-24.8) | 6 (3-15.2) |
| Postoperative day 5 | 0.9 (0.2-2.7) | 6.9 (2.9-12.6) | 4.5 (3.3-7) | 25.9(25.9-25.9) | 5.5 (3.3-17.2) |
| Survival | |||||
| median (days) | 1589 (1212-1965) | 469 (230-707) | 500 (193-806) | 1302 (1123-1481) | |
| 1 years-survival (%) | 0.81 ( 0.72- 0.88) | 0.64 (0.34-0.83) | 1 | 0.89 (0.43- 0.98) | |
| 3 years-survival (%) | 0.62 (0.51- 0.71) | 0.21 (0.05- 0.44) | . | . | 0.56 (0.20- 0.80) |
CCA, cholangiocarcinoma; MF, mass-forming; PI, periductal-infiltration; FN, flat and nodular infiltration; IG, intraductal- growth; PP, papillary-polypoid; IVC, inferior venacava; EBL, estimated blood loss; SD, standard deviation; LOS, length of hospital stays; AST, aspartate aminotransferase; ALT, Alanine aminotransferase; ALP, alkaline phosphatase